Background: Opioids are psychoactive analgesic drugs prescribed for pain relief and palliative care. Due to their addictive potential, effort and vigilance in controlling prescriptions is needed to avoid misuse and dependence. Despite the effort, the prevalence of opioid use disorder continues to rise. Opioid substitution therapies are commonly used to treat opioid dependence; however, there is minimal consensus as to which therapy is most effective. Available treatments include methadone, heroin, buprenorphine, as well as naltrexone. This systematic review aims to assess and compare the effect of all available opioid substitution therapies on the treatment of opioid dependence.
Methods/design: The authors will search Medline, EMBASE, PubMed, PsycINFO, Web of Science, Cochrane Library, Cochrane Clinical Trials Registry, World Health Organization International Clinical Trials Registry Platform Search Portal, and the National Institutes for Health Clinical Trials Registry. The title, abstract, and full-text screening will be completed in duplicate. When appropriate, multiple treatment comparison Bayesian meta-analytic methods will be performed to deduce summary statistics estimating the effectiveness of all opioid substitution therapies in terms of retention and response to treatment (as measured through continued opioid abuse).
Discussion: Using evidence gained from this systematic review, we anticipate disseminating an objective review of the current available literature on the effectiveness of all opioid substitution therapies for the treatment of opioid use disorder. The results of this systematic review are imperative to the further enhancement of clinical practice in addiction medicine.
Systematic Review Registration: PROSPERO CRD42013006507.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171401 | PMC |
| http://dx.doi.org/10.1186/2046-4053-3-105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Buprenorphine and postpartum contraception utilization among people with opioid use disorder: a multi-state analysis.
Addict Sci Clin Pract
January 2025
Departments of Family and Community Medicine and Health and Clinical Outcomes Research, Saint Louis University School of Medicine, Saint Louis, MO, USA.
Background: The postpartum period provides an opportunity for birthing people with opioid use disorder (OUD) to consider their future reproductive health goals. However, the relationship between the use of medication for opioid use disorder (MOUD) and contraception utilization is not well understood. We used multistate administrative claims data to compare contraception utilization rates among postpartum people with OUD initiating buprenorphine (BUP) versus no medication (psychosocial services receipt without MOUD (PSY)) in the United States (US).
View Article and Find Full Text PDFBenzodiazepine agonist treatment for patients with benzodiazepine dependence undergoing opioid agonist treatment: a study protocol for the randomized controlled trial BMX-BAR.
Trials
January 2025
Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Background: There is a lack of knowledge on effective treatment methods for comorbid benzodiazepine dependence in populations undergoing opioid agonist treatment (OAT). Tapering and discontinuation of benzodiazepines has long been considered the standard treatment, even though there is limited evidence for this practice. There is also limited research on benzodiazepine agonist treatment; however, peer and clinical experiences indicate that such approaches may be beneficial for a subgroup of the patients with long-lasting benzodiazepine dependence not responding to other treatment approaches.
View Article and Find Full Text PDF"It's a delicate balance": clinicians' experiences of providing heroin-assisted treatment.
Harm Reduct J
December 2024
Unit for Clinical Research on Addictions, Oslo University Hospital Health Trust, PB 4959 Nydalen, Oslo, 0424, Norway.
Background: Little attention has been paid to the experiences of clinicians and health personnel who provide heroin-assisted treatment (HAT). This study provides the first empirical findings about the clinicians' experiences of providing HAT in the Norwegian context.
Methods: 23 qualitative interviews were conducted with 31 clinicians shortly after HAT clinics opened in Norway's two largest cities: Oslo and Bergen.
Social support status and associated factors among methadone maintenance patients: a multicentre, cross-sectional study in Vietnam during the COVID-19 pandemic.
BMJ Open
December 2024
Faculty of Pharmaceutical Management and Economics, Hanoi University of Pharmacy, Hanoi, Vietnam
Objectives: To investigate the social support status and associated factors among Vietnamese methadone maintenance patients during the COVID-19 pandemic.
Design: Cross-sectional study.
Setting: Three methadone clinics.
Metabolic Syndrome as a Risk Factor Among Lebanese Patients with Substance Use Disorder Undergoing Treatment for Recovery Through Rehabilitation or Opioid Substitution Treatment.
Clin Pract
December 2024
Department of Nutrition and Food Science, Faculty of Arts and Sciences, Lebanese American University, Byblos P.O. Box 36, Lebanon.
Data about metabolic syndrome (MS) in people who use drugs (PWUD) undergoing treatment for recovery are limited. We aimed to explore the extent of the MS and its predominant components and determinants in a sample of PWUD undergoing treatment for recovery through rehabilitation or opioid substitution treatment (OST) in Lebanon. Furthermore, we investigated the effect of each treatment modality on the MS; This was a cross-sectional study, in which demographics and treatment-related, nutritional, and biochemical data of the participants were collected.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!